Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

New Ray Medicine
新 銳 醫 藥

New Ray Medicine International Holding Limited
新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

PROFIT WARNING

This announcement is made by New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (“**Directors**”) of the Company (“**Board**”) wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that, based on a preliminary review and analysis of the latest available unaudited consolidated management accounts of the Company, it is expected that the Group will record a substantial increase in loss for the six months ended 30 June 2017 (“**1H 2017**”) as compared to a loss of approximately HK$420,000 recorded by the Group for the six months ended 30 June 2016 (“**1H 2016**”). Such substantial increase in loss was mainly attributable to the impairment losses of the Group’s available-for-sale investments of approximately HK$65.4 million for 1H 2017 (“**2017 Impairment Losses**”) as a result of the volatile stock market in Hong Kong in the first half of 2017 as compared to the impairment losses of the Group’s available-for-sale investments of approximately HK$440,000 for 1H 2016. The Board wishes to emphasis that the 2017 Impairment Losses are non-cash in nature which did not affect working capital sufficiency of the Group during 1H 2017. The 2017 Impairment Losses were mostly related to the impairment losses on the investment in Town Health International Medical Group Limited ("**TH**") (Stock Code: 3886). As at 30 June 2017, the Group held 120,000,000 shares of TH as available-for-sale investment, representing approximately 1.6% of its issued shares. The Group recorded an impairment loss on its investment in the shares of TH of approximately HK$62.8 million for 1H 2017.

The Company is still in the process of finalising its unaudited consolidated financial statements for 1H 2017. The information contained in this announcement is only based on the preliminary assessment made by the Board with reference to the information currently available, which has not been reviewed or audited by the auditors of the Company and may be subject to change. Shareholders and potential investors are advised to refer to the details of the Group's financial results for 1H 2017, which are expected to be published in August 2017.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

On behalf of the Board
New Ray Medicine International Holding Limited
Zhou Ling
Chairman & Executive Director

Hong Kong, 11 July 2017

As of the date of this announcement, the executive Directors are Mr. Zhou Ling and Ms. Yang Fang; and the independent non-executive Directors are Mr. Ho Hau Cheung, BBS, MH, Mr. Leung Chi Kin and Ms. Li Sin Ming, Ivy.